Innate Pharma S.A./€IPH
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Innate Pharma S.A.
Innate Pharma S.A. is a clinical-stage biotechnology company specializing in immuno-oncology, focusing on developing therapeutic antibodies that engage the innate immune system to treat cancer. Its pipeline includes lacutamab, an anti-KIR3DL2 antibody in Phase II trials for cutaneous and peripheral T-cell lymphomas, and monalizumab, an immune checkpoint inhibitor in Phase III trials for advanced solid tumors. Founded in 1999 and headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, the company has established collaborations with biopharmaceutical firms such as AstraZeneca and Sanofi. Innate Pharma's proprietary ANKET® platform focuses on developing multi-specific NK cell engagers, positioning the company in the field of natural killer cell therapeutics.
Ticker
€IPH
Sector
Primary listing
PAR
Employees
181
Headquarters
Website
IPH Metrics
BasicAdvanced
€182M
-
-€0.61
0.96
-
Price and volume
Market cap
€182M
Beta
0.96
52-week high
€2.50
52-week low
€1.33
Average daily volume
80K
Financial strength
Current ratio
2.6
Quick ratio
2.499
Long term debt to equity
252.275
Total debt to equity
350.86
Interest coverage (TTM)
-91.12%
Profitability
EBITDA (TTM)
-49.581
Gross margin (TTM)
-158.34%
Net profit margin (TTM)
-245.87%
Operating margin (TTM)
-256.32%
Revenue per employee (TTM)
€110,000
Management effectiveness
Return on assets (TTM)
-21.84%
Return on equity (TTM)
-162.91%
Valuation
Price to revenue (TTM)
7.944
Price to book
18.71
Price to tangible book (TTM)
18.71
Price to free cash flow (TTM)
-21.934
Free cash flow yield (TTM)
-4.56%
Free cash flow per share (TTM)
-0.09
Growth
Revenue change (TTM)
-67.36%
Earnings per share change (TTM)
548.69%
3-year revenue growth (CAGR)
-6.61%
10-year revenue growth (CAGR)
10.19%
3-year earnings per share growth (CAGR)
-2.76%
10-year earnings per share growth (CAGR)
4.53%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Innate Pharma S.A. stock?
Innate Pharma S.A. (IPH) has a market cap of €182M as of August 22, 2025.
What is the P/E ratio for Innate Pharma S.A. stock?
The price to earnings (P/E) ratio for Innate Pharma S.A. (IPH) stock is 0 as of August 22, 2025.
Does Innate Pharma S.A. stock pay dividends?
No, Innate Pharma S.A. (IPH) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next Innate Pharma S.A. dividend payment date?
Innate Pharma S.A. (IPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Innate Pharma S.A.?
Innate Pharma S.A. (IPH) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.